Amoeba SA (FR:ALMIB) has released an update.
Amoeba SA, a French greentech firm, reported positive results from a clinical study on a new cosmetic ingredient, showing significant skin care benefits such as improved dermis thickness and skin density. The company has successfully listed the ingredient on the INCI, enabling immediate marketing and partnership opportunities. This development aligns with Amoeba’s aim to be a leader in microbiological risk management across various sectors, and they will discuss their strategy further at an upcoming conference in Paris.
For further insights into FR:ALMIB stock, check out TipRanks’ Stock Analysis page.
